Skip to content
10-Q

Quarterly Report

REGENERON PHARMACEUTICALS, INC. REGN

0000872589-26-000016

← back to feed
Filed
Apr 29, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 107.7M sh
Shares Diluted Q1 2026 · Mar 31, 2025 111.2M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $794.3M
Stock Repurchased Q1 2026 · Mar 31, 2025 $1.04B
Dividends Paid Q1 2026 · Mar 31, 2026 $97.8M
Dividends Paid Q1 2026 · Mar 31, 2025 $93.8M
Capex Q1 2026 · Mar 31, 2026 $230.6M
Capex Q1 2026 · Mar 31, 2025 $229.3M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $1.08B
Operating Cash Flow Q1 2026 · Mar 31, 2025 $1.05B
Long Term Debt Q1 2026 · Mar 31, 2026 $1.99B
Long Term Debt Q1 2026 · Dec 31, 2025 $1.99B
Cash And Equivalents Q1 2026 · Mar 31, 2026 $2.96B
Cash And Equivalents Q1 2026 · Dec 31, 2025 $3.12B
Cash And Equivalents Q1 2026 · Mar 31, 2025 $3.09B
Stockholders Equity Q1 2026 · Mar 31, 2026 $31.42B
Stockholders Equity Q1 2026 · Dec 31, 2025 $31.26B
Stockholders Equity Q1 2026 · Mar 31, 2025 $29.39B
Stockholders Equity Q1 2026 · Dec 31, 2024 $29.35B
Current Liabilities Q1 2026 · Mar 31, 2026 $5.11B
Current Liabilities Q1 2026 · Dec 31, 2025 $4.37B
Total Liabilities Q1 2026 · Mar 31, 2026 $9.45B
Total Liabilities Q1 2026 · Dec 31, 2025 $9.3B
Current Assets Q1 2026 · Mar 31, 2026 $18.21B
Current Assets Q1 2026 · Dec 31, 2025 $18.02B
Total Assets Q1 2026 · Mar 31, 2026 $40.87B
Total Assets Q1 2026 · Dec 31, 2025 $40.56B
Eps Diluted Q1 2026 · Mar 31, 2026 $6.75
Eps Diluted Q1 2026 · Mar 31, 2025 $7.27
Eps Basic Q1 2026 · Mar 31, 2026 $6.99
Eps Basic Q1 2026 · Mar 31, 2025 $7.58
Sga Expense Q1 2026 · Mar 31, 2026 $647.7M
Sga Expense Q1 2026 · Mar 31, 2025 $633M
Rd Expense Q1 2026 · Mar 31, 2026 $1.54B
Rd Expense Q1 2026 · Mar 31, 2025 $1.33B
Net Income Q1 2026 · Mar 31, 2026 $727.2M
Net Income Q1 2026 · Mar 31, 2025 $808.7M
Operating Income Q1 2026 · Mar 31, 2026 $642.9M
Operating Income Q1 2026 · Mar 31, 2025 $591.7M
Revenue Q1 2026 · Mar 31, 2026 $3.61B
Revenue Q1 2026 · Mar 31, 2025 $3.03B